These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18297716)

  • 1. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
    Gopal K; Johnson TC; Gopal S; Walfish A; Bang CT; Suwandhi P; Pena-Sahdala HN; Clain DJ; Bodenheimer HC; Min AD
    Hepatology; 2006 Aug; 44(2):335-40. PubMed ID: 16871569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection.
    Rosenberg P; Hagen K
    J Viral Hepat; 2011 Feb; 18(2):129-34. PubMed ID: 20196801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
    Poustchi H; Negro F; Hui J; Cua IH; Brandt LR; Kench JG; George J
    J Hepatol; 2008 Jan; 48(1):28-34. PubMed ID: 17977612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C virus management: 2000-2005 update.
    Hughes CA; Shafran SD
    Ann Pharmacother; 2006 Jan; 40(1):74-82. PubMed ID: 16368925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
    Colombatto P; Ciccorossi P; Maina AM; Civitano L; Oliveri F; Coco B; Romagnoli V; Bonino F; Brunetto MR
    Clin Pharmacol Ther; 2008 Aug; 84(2):212-5. PubMed ID: 18388885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection.
    Hanouneh IA; Feldstein AE; Lopez R; Yerian L; Pillai A; Zein CO; Zein NN
    Clin Gastroenterol Hepatol; 2008 May; 6(5):584-9. PubMed ID: 18455698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
    Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
    Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
    Petta S; Macaluso FS; Cammà C; Marco VD; Cabibi D; Craxì A
    Liver Int; 2012 Oct; 32(9):1443-50. PubMed ID: 22764879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection.
    Hsu SJ; Hsu CS; Liu CH; Liu CJ; Chen CL; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(2):227-35. PubMed ID: 21447872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.